CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme

Adult Glioblastoma Clinical Trial

Official title:

A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00016328
• Other study ID #: NCI-2012-01858
• Secondary ID: N997BCDR00000686
• Status: Completed
• Phase: Phase 2
• First received: May 6, 2001
• Last updated: July 17, 2013
• Start date: May 2001

Study information

• Verified date: June 2013
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Phase II trial to study the effectiveness of CCI-779 in treating patients who have recurrent glioblastoma multiforme. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Description:

OBJECTIVES:

I. Determine the efficacy of CCI-779, in terms of the percentage of patients who are progression-free at 6 months, time to progression, and time to death, in patients with recurrent glioblastoma multiforme.

II. Determine the toxic effects of this drug in these patients. III. Correlate molecular alterations in the tumors of these patients with response to treatment with this drug.

OUTLINE: This is a multicenter study. Patients are stratified according to concurrent P450 anticonvulsant use (yes vs no).

Patients receive CCI-779 IV over 30 minutes once weekly for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed every 6 months for 5 years and then annually for up to 10 years.

PROJECTED ACCRUAL: A total of 63 patients will be accrued for this study within 39 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. primary completion date: August 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed grade 4 astrocytoma at primary diagnosis or recurrence

• Gliosarcoma allowed

• Evidence of tumor progression by MRI or CT scan after radiotherapy or first-line chemotherapy

• Measurable or evaluable disease by MRI or CT scan

• Performance status - ECOG 0-2

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

• Hemoglobin at least 9 g/dL

• Bilirubin no greater than 1.5 mg/dL

• SGOT no greater than 3 times upper limit of normal

• Creatinine no greater than 2.0 mg/dL

• No myocardial infarction within the past 6 months

• No congestive heart failure requiring ongoing maintenance therapy for life-threatening ventricular arrhythmias

• Cholesterol no greater than 350 mg/dL

• Triglycerides no greater than 400 mg/dL

• Willing to provide correlative laboratory samples

• No uncontrolled infection

• No known hypersensitivity to any components of CCI-779, diphenhydramine hydrochloride, or other similar antihistamines

• No other medical reason that would preclude diphenhydramine premedication

• No other active malignancy

• No other severe disease that would preclude study participation

• Not immunocompromised unless due to corticosteroids

• HIV negative

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• See Disease Characteristics

• Prior adjuvant chemotherapy allowed

• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)

• No more than 1 prior chemotherapy regimen for recurrent/progressive disease

• No prior polifeprosan 20 with carmustine implant (Gliadel)

• Must be on fixed dose of corticosteroids (or no corticosteroids) at least 1 week prior to baseline scan

• See Disease Characteristics

• At least 12 weeks since prior radiotherapy

• No prior stereotactic radiosurgery or interstitial brachytherapy unless there is a separate lesion on MRI that is outside of the previously treated field

• No prior resection since last chemotherapy or radiotherapy unless there is unequivocal tumor growth on neuro-imaging study since surgery or there is a separate lesion not present in the surgical bed

• More than 4 weeks since prior investigational agents

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adult Giant Cell Glioblastoma
• Adult Glioblastoma
• Adult Gliosarcoma
• Glioblastoma
• Gliosarcoma
• Recurrent Adult Brain Tumor

Intervention

Drug:
• temsirolimus
Given IV

Other:
• laboratory biomarker analysis
Correlative studies
• pharmacological study
Correlative studies

Locations

Country	Name	City	State
United States	North Central Cancer Treatment Group	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients being progression free	Ninety-five percent confidence intervals for the true proportion will be calculated according to the approach of Duffy and Santner.	6 months	No
Secondary	Percentage of patients that have not progressed	Ninety-five percent confidence intervals for the true proportion will be calculated according to the approach of Duffy and Santner.	3 months	No
Secondary	Percentage of patients that have not progressed	Ninety-five percent confidence intervals for the true proportion will be calculated according to the approach of Duffy and Santner.	12 months	No
Secondary	Percentage of patients that have not progressed	Ninety-five percent confidence intervals for the true proportion will be calculated according to the approach of Duffy and Santner.	18 months	No
Secondary	Confirmed tumor response defined as an objective status of complete response (CR), partial response (PR), or regression (REGR) on two consecutive evaluations	Ninety-five percent confidence intervals for the true proportion will be calculated using the exact binomial method.	Up to 10 years	No
Secondary	Time to progression and death	Estimated using Kaplan-Meier. Frequency distributions of baseline patient characteristics will be compared using chi-squared and Wilcoxon tests.	Up to 10 years	No